1
|
van Hage M, Polovic N, Wadén K, Binnmyr J, Hamsten C, Grönneberg R, Palmberg C, Milcic-Matic N, Bergman T, Grönlund H. Diversity of allergens contained in dog saliva. Reply. Allergy 2013; 68:1485-1486. [PMID: 24498643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
2
|
Codina R, van Hage M, Polovic N, Wadén K, Binnmyr J, Hamsten C, Grönneberg R, Palmberg C, Milcic-Matic N, Bergman T, Grönlund H. Diversity of allergens contained in dog saliva. Allergy 2013; 68:1484-5. [PMID: 24351070 DOI: 10.1111/all.12264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- R. Codina
- Greer Laboratories, Inc.; Lenoir NC USA
| | - M. van Hage
- Department of Medicine; Clinical Immunology and Allergy Unit; Karolinska Institutet; Stockholm Sweden
| | - N. Polovic
- Department of Medicine; Clinical Immunology and Allergy Unit; Karolinska Institutet; Stockholm Sweden
- Department of Biochemistry; Faculty of Chemistry; University of Belgrade; Belgrade Serbia
| | - K. Wadén
- Department of Medicine; Clinical Immunology and Allergy Unit; Karolinska Institutet; Stockholm Sweden
| | - J. Binnmyr
- Department of Medicine; Clinical Immunology and Allergy Unit; Karolinska Institutet; Stockholm Sweden
| | - C. Hamsten
- Department of Medicine; Clinical Immunology and Allergy Unit; Karolinska Institutet; Stockholm Sweden
- Center for Inflammatory Diseases; Karolinska Institutet; Stockholm
| | - R. Grönneberg
- Department of Medicine; Respiratory Medicine Unit; Karolinska Institutet; Stockholm
| | - C. Palmberg
- Department of Medical Biochemistry and Biophysics; Karolinska Institutet; Stockholm Sweden
| | - N. Milcic-Matic
- Department of Dermatology; Faculty of Veterinary Medicine; University of Belgrade; Belgrade Serbia
| | - T. Bergman
- Department of Medical Biochemistry and Biophysics; Karolinska Institutet; Stockholm Sweden
| | - H. Grönlund
- Department of Medicine; Clinical Immunology and Allergy Unit; Karolinska Institutet; Stockholm Sweden
- Department of Clinical Neuroscience; Therapeutic Immune Design Unit; Karolinska Institutet; Stockholm Sweden
| |
Collapse
|
3
|
Polovic N, Wadén K, Binnmyr J, Hamsten C, Grönneberg R, Palmberg C, Milcic‐Matic N, Bergman T, Grönlund H, Hage M. Dog saliva - an important source of dog allergens. Allergy 2013; 68:585-92. [PMID: 23464525 PMCID: PMC3652036 DOI: 10.1111/all.12130] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/07/2013] [Indexed: 11/27/2022]
Abstract
BACKGROUND Allergy to dog (Canis familiaris) is a worldwide common cause of asthma and allergic rhinitis. However, dander extract in routine diagnostics is not an optimal predictor of IgE-mediated dog allergy. Our objective was to evaluate saliva as an allergen source for improved diagnostics of allergy to dog. METHODS IgE-binding proteins in dog saliva and dander extract were analysed by immunoblot and mass spectrometry (LC-MS/MS) using pooled or individual sera from dog-allergic patients (n = 13). Sera from 59 patients IgE positive to dander and 55 patients IgE negative to dander but with symptoms to dog were analysed for IgE against saliva and dander by ELISA. Basophil stimulation with dog saliva and dander extract was measured by flow cytometry among three dog-allergic patients. Additionally, IgE-binding protein profiles of saliva from different breeds were investigated by immunoblot. RESULTS Greater number and diversity of IgE-binding proteins was found in saliva compared to dander extract and varied among dog breeds. In saliva, Can f 1, 2, 3 and 6 were identified but also four new saliva allergen candidates. The majority of the 59 dog dander-positive sera (n = 44) were IgE positive to dog saliva. Among patients IgE negative to dander, but with symptoms to dog, 20% were IgE positive to saliva. The biological activity of saliva was confirmed by basophil degranulation. CONCLUSIONS Dog saliva is an allergen source for improved diagnostics of dog allergy. The IgE-binding protein profile of saliva from different dogs varies.
Collapse
Affiliation(s)
- N. Polovic
- Department of Medicine Solna, Clinical Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
- Department of Biochemistry Faculty of Chemistry University of Belgrade Belgrade Serbia
| | - K. Wadén
- Department of Medicine Solna, Clinical Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
| | - J. Binnmyr
- Department of Medicine Solna, Clinical Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
| | - C. Hamsten
- Department of Medicine Solna, Clinical Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
- Center for Inflammatory Diseases Karolinska Institutet StockholmSweden
| | - R. Grönneberg
- Department of Medicine Solna, Respiratory Medicine Unit Karolinska Institutet StockholmSweden
| | - C. Palmberg
- Department of Medical Biochemistry and Biophysics Karolinska Institutet Stockholm Sweden
| | - N. Milcic‐Matic
- Department of Dermatology Faculty of Veterinary Medicine University of Belgrade Belgrade Serbia
| | - T. Bergman
- Department of Medical Biochemistry and Biophysics Karolinska Institutet Stockholm Sweden
| | - H. Grönlund
- Department of Medicine Solna, Clinical Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
- Department of Clinical Neuroscience Therapeutic Immune Design Unit Karolinska Institutet Stockholm Sweden
| | - M. Hage
- Department of Medicine Solna, Clinical Immunology and Allergy Unit Karolinska Institutet Stockholm Sweden
| |
Collapse
|
4
|
Bergman T, Zhang K, Palmberg C, Jörnvall H, Auld DS. Zinc binding to peptide analogs of the structural zinc site in alcohol dehydrogenase: implications for an entatic state. Cell Mol Life Sci 2009; 65:4019-27. [PMID: 18850316 DOI: 10.1007/s00018-008-8379-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Zinc binding to the peptide replica and analogs to residues 93-115 of horse liver alcohol dehydrogenase (ADH) was examined by competition of the peptides and the chromophoric chelator 4-(2- pyridylazo)resorcinol for zinc and X-ray absorption fine structure analysis of the zinc ligands. In the enzyme, zinc is coordinated by four Cys residues. In the peptide replica, zinc is bound to three Cys and one His residue. A four-Cys zinc coordination is observed only when His is removed, leading to increased zinc stability. ADH crystal structures reveal that the epsilon-amino group of the conserved residue Lys323 is within H-bond distance of the backbone amide oxygens of residues 103, 105 and 108, likely stabilizing the zinc coordination in the enzyme. The peptide data thus indicate structural strain and increased energy in the zinc-binding site in the protein, characteristic of an entatic state, implying a functional nature for this zinc site.
Collapse
Affiliation(s)
- T Bergman
- Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | | | |
Collapse
|
5
|
Jägerbrink T, Lexander H, Palmberg C, Shafqat J, Sharoyko V, Berggren PO, Efendic S, Zaitsev S, Jörnvall H. Differential protein expression in pancreatic islets after treatment with an imidazoline compound. Cell Mol Life Sci 2007; 64:1310-6. [PMID: 17458497 DOI: 10.1007/s00018-007-7136-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The effects of an imidazoline compound (BL11282) on protein expression in rat pancreatic islets were investigated with a proteomic approach. The compound increases insulin release selectively at high glucose concentrations and is therefore of interest in type 2 diabetes. Whole cell extracts from isolated drug-treated and native pancreatic rat islets were compared after separation by 2-D gel electrophoresis. Differentially expressed proteins were identified by mass spectrometry; 15 proteins were selectively up-regulated and 7 selectively down-regulated in drug-treated islets. Of special interest among the differentially expressed proteins are those involved in protein folding (Hsp60, protein disulfide isomerase, calreticulin), Ca(2+) binding (calgizzarin, calcyclin and annexin I) and metabolism or signalling (pyruvate kinase, alpha enolase and protein kinase C inhibitor 1).
Collapse
Affiliation(s)
- T Jägerbrink
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Roblick UJ, Hirschberg D, Habermann JK, Palmberg C, Becker S, Krüger S, Gustafsson M, Bruch HP, Franzén B, Ried T, Bergmann T, Auer G, Jörnvall H. Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci 2004; 61:1246-55. [PMID: 15141310 DOI: 10.1007/s00018-004-4049-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Changes in the proteome of colon mucosal cells accompany the transition from normal mucosa via adenoma and invasive cancer to metastatic disease. Samples from 15 patients with sporadic sigmoid cancers were analyzed. Proteins were separated by two-dimensional gel electrophoresis. Relative differences in expression levels between normal tissue, adenoma, carcinoma and metastasis were evaluated in both intra- and inter-patient comparisons. Up- and down-regulated proteins (> twofold) during development to cancer or metastasis were excised and submitted to peptide mass fingerprinting and MS/MS sequence analysis, facilitated by the use of a compact disc workstation. In total, 112 protein spots were found to be differentially regulated, of which 72 were determined as to protein identity, 46 being up-regulated toward the progression of cancer, and 26 down-regulated. Several of the identifications correlate with proteins of the cell cycle, cytoskeleton or metabolic pathways. The pattern changes now identified have the potential for design of marker panels for assistance in diagnostics and therapeutic strategies in colorectal cancer.
Collapse
Affiliation(s)
- U J Roblick
- Department of Oncology and Pathology, Unit of Cancer Proteomics, Karolinska Institutet and Hospital, 171 76 Stockholm, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Bandholtz L, Guo Y, Palmberg C, Mattsson K, Ohlsson B, High A, Shabanowitz J, Hunt DF, Jörnvall H, Wigzell H, Agerberth B, Gudmundsson GH. Hsp90 binds CpG oligonucleotides directly: implications for hsp90 as a missing link in CpG signaling and recognition. Cell Mol Life Sci 2003; 60:422-9. [PMID: 12678505 DOI: 10.1007/s000180300035] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
CpG motifs originating from bacterial DNA (CpG DNA) can act as danger signals for the mammalian immune system. These CpG DNA motifs like many other pathogen-associated molecular patterns are believed to be recognized by a member of the toll-like receptor family, TLR-9. Here we show results suggesting that heat shock protein 90 (hsp90) is also implicated in the recognition of CpG DNA. Hsp90 was characterized as a binder to oligodeoxynucleotides (ODNs) containing CpG motifs (CpG ODNs) after several purification steps from crude protein extracts of peripheral blood mononuclear cells. This finding was further supported by direct binding of CpG ODNs to commercially available human hsp90. Additionally, immunohistochemistry studies showed redistribution of hsp90 upon CpG ODN uptake. Thus, we propose that hsp90 can act as a ligand transfer molecule and/or play a central role in the signaling cascade induced by CpG DNA.
Collapse
Affiliation(s)
- L Bandholtz
- Microbiology and Tumor Biology Center (MTC), Karolinska Institutet, 17177, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Jonsson AP, Aissouni Y, Palmberg C, Percipalle P, Nordling E, Daneholt B, Jornvall H, Bergman T. Recovery of gel-separated proteins for in-solution digestion and mass spectrometry. Anal Chem 2001; 73:5370-7. [PMID: 11816562 DOI: 10.1021/ac010486h] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A protocol for mass spectrometry of gel-separated proteins resulting in significantly increased sequence coverage and in improved possibilities for detection and identification of posttranslational modifications was developed. In relation to the standard in-gel digestion procedure, the sequence coverage using a combination of matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry was on the average increased by 30%. The method involves electroblotting of the gel-separated proteins to a poly(vinylidene difluoride) membrane. The proteins are extracted from the membrane using a solution of 1% trifluoroacetic acid in 70% acetonitrile and lyophilized. After reconstitution of the protein extract in digestion buffer, proteolytic cleavage is carried out in-solution as opposed to the standard in-gel digestion procedure. This allows recovery of large and hydrophobic peptides for mass spectrometry and reduces the risk for entrapment of proteolytic peptides in the gel matrix. The method was applied to proteins in the 30-40-kDa range with highly different structural properties. The improved ability to localize and determine protein modifications is shown for N-terminal acetylation and methylation of a histidine residue. Furthermore, the method enables fast screening of homologous protein sequences.
Collapse
Affiliation(s)
- A P Jonsson
- Department of Medical Biochemistry and Biophysics, Medical Nobel Institute, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Haapala K, Rökman A, Palmberg C, Hyytinen ER, Laurila M, Tammela TL, Koivisto PA. Chromosomal changes in locally recurrent, hormone-refractory prostate carcinomas by karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001; 131:74-8. [PMID: 11734323 DOI: 10.1016/s0165-4608(01)00491-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The genetic mechanisms of prostate cancer recurrence during hormonal therapy are largely unknown. So far, data from conventional karyotype analysis on hormone-refractory prostate carcinomas have not been published, mainly because of the difficulties in obtaining fresh hormone-refractory prostate carcinoma samples and getting metaphases from them. Here, we have studied chromosomal changes in 12 locally recurrent, hormone-refractory prostate carcinomas using karyotyping and CGH that revealed genetic aberrations in all tumors. Loss of the Y chromosome was the most common (89%) finding, and tetraploidy or near-tetraploidy was detected in all tumors. Also non-random translocations were found in 56% of the tumors. The present study indicates that clonal chromosomal aberrations in hormone-refractory prostate carcinomas are more common than in untreated primary tumors, and also, further studies on the frequency and significance of translocations in prostate carcinoma progression during hormonal therapy are warranted.
Collapse
Affiliation(s)
- K Haapala
- Department of Clinical Genetics, Tampere University Hospital, P.O. Box 2000, FIN-33521, Tampere, Finland
| | | | | | | | | | | | | |
Collapse
|
10
|
Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164:1992-5. [PMID: 11061898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
PURPOSE Amplification of the androgen receptor gene has been found in a third of hormone refractory prostate carcinomas. It is possible that amplification facilitates cell growth ability in low concentrations of androgens remaining in the serum after androgen deprivation therapy. We evaluate whether androgen receptor gene amplification at primary progression is associated with response to second line combined androgen blockade for prostate cancer. MATERIALS AND METHODS A total of 77 patients with prostate cancer were treated initially with androgen deprivation monotherapy followed by combined androgen blockade after the first progression. After initiation of second line combined androgen blockade patients were followed every 3 months to evaluate treatment responses. Biopsies were taken from the prostate at the first progression under endocrine monotherapy. Androgen receptor gene copy number was determined by fluorescence in situ hybridization. RESULTS Androgen receptor gene amplification was found in 10 of the 77 cases (13%) at the primary disease progression, and was associated with a favorable response to second line combined androgen blockade. Only 1 of 34 (3%) patients classified as nonresponders had androgen receptor gene amplification, whereas 9 of 41 (21%) classified as having either stable disease or response had amplification (p = 0.016). Patients with androgen receptor gene amplification also had a decrease in prostate specific antigen more often after combined androgen blockade than those with no amplification (p = 0.079). However, androgen receptor gene amplification was not associated with patient survival after the first progression. CONCLUSIONS Androgen receptor gene amplification detected in tumors progressing during androgen deprivation monotherapy is associated with favorable treatment response to second line combined androgen blockade. This finding suggests that at least some androgen receptor amplified tumors retain a high degree of dependency on residual androgens remaining in serum after monotherapy.
Collapse
Affiliation(s)
- C Palmberg
- Division of Urology, Tampere University Hospital, Finland
| | | | | | | | | | | |
Collapse
|
11
|
Palmberg C, Rantala I, Tammela TL, Helin H, Koivisto PA. Low apoptotic activity in primary prostate carcinomas without response to hormonal therapy. Oncol Rep 2000; 7:1141-4. [PMID: 10948353 DOI: 10.3892/or.7.5.1141] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Proliferative and apoptotic activities, as well as p53 protein expression, of ten untreated primary prostate carcinomas that showed extremely poor response to hormonal therapy (primary androgen independent prostate carcinomas) were compared with the stage- and grade-matched primary tumor specimens with favorable response to hormonal therapy (androgen dependent prostate carcinomas). The mean proliferative activity measured by Ki-67 immunohistochemistry was slightly higher in the primary androgen independent prostate carcinomas (8.70+/-5.24) than in the androgen dependent prostate carcinomas (7.09+/-2.68; p=0.27). The mean apoptotic activity by in situ end-labeling technique in the primary androgen independent prostate carcinomas (0.96+/-1.03) was less than half of that in the androgen dependent prostate carcinomas (2.75+/-0.98; p=0.0001). Ten percent of the androgen dependent prostate tumors showed p53 protein expression, whereas 30% of the primary androgen independent prostate tumors were immunopositive for p53 (p=0.30). In summary, we have shown that apoptotic activity in the primary androgen independent prostate carcinomas is significantly lower than in the matched androgen dependent prostate carcinomas while the proliferative activity remains unaffected. These results suggest that primary androgen independent prostate carcinomas may have genetic properties, such as inactivation of the p53 gene, that enable them to escape apoptosis caused by androgen ablation.
Collapse
Affiliation(s)
- C Palmberg
- Department of Surgery, Pietarsaari Hospital, FIN-68601 Pietarsaari, Finland
| | | | | | | | | |
Collapse
|
12
|
Abstract
OBJECTIVE The aim of this study was to estimate the prevalence of primary hormone-refractory prostate cancer and to evaluate the prognostic value of decline of prostate-specific antigen (PSA) after primary hormonal therapy. MATERIAL AND METHODS The material consisted of 236 consecutive, hormonally treated prostate cancer patients, whose clinicopathological findings, as well as serum PSA values, were retrieved from patient files. Multivariate analysis was performed based on the PSA decline at 12 months from the commencement of therapy and patients were thereafter categorised into four groups: complete response (CR), partial response (PR), stable disease (SD), and no response (NR) according to the biochemical response. RESULTS Only 14 (5.9%) of the patients were included in the NR group, i.e. PSA declined less than 50%, suggesting that primary androgen-independent prostate cancer is uncommon. The PSA decline was significantly (p < 0.001) associated with cancer-specific survival. Patients with CR had a median survival of more than 6 years, whereas those with NR had a median survival of only 14 months. In multivariate analysis, PSA decline showed independent prognostic value together with M-stage and histological grade. CONCLUSIONS Primary prostate cancer is probably even more sensitive to hormonal treatment than previously assumed, and PSA decline seems to be useful in predicting disease outcome after hormonal therapy.
Collapse
Affiliation(s)
- C Palmberg
- Division of Urology, Tampere University Hospital, Tampere, Finland.
| | | | | | | |
Collapse
|
13
|
Bergman T, Palmberg C, Jörnvall H, Auld DS, Vallee BL. Zinc binding characteristics of the synthetic peptide corresponding to the structural zinc site of horse liver alcohol dehydrogenase. Adv Exp Med Biol 1999; 463:339-42. [PMID: 10352703 DOI: 10.1007/978-1-4615-4735-8_41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- T Bergman
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | |
Collapse
|
14
|
Palmberg C, Kylmala T, Tammela T. Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Br J Urol 1997; 79:808-9. [PMID: 9158528 DOI: 10.1046/j.1464-410x.1997.00197.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- C Palmberg
- Tampere University Hospital, Division of Urology, Finland
| | | | | |
Collapse
|
15
|
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57:314-9. [PMID: 9000575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Progression of prostate cancer during endocrine therapy is a major clinical problem, the molecular mechanisms of which remain poorly understood. Amplification of the androgen receptor (AR) gene was recently described in recurrent prostate carcinomas from patients who had failed androgen deprivation therapy. To evaluate the hypothesis that amplification of the AR gene is a cause for the failure of androgen deprivation therapy in prostate cancer, we studied whether AR amplification leads to gene overexpression, whether the amplified AR gene is structurally intact, and whether tumors with AR amplification have distinct biological and clinical characteristics. Tumor specimens were collected from 54 prostate cancer patients at the time of a local recurrence following therapy failure. In 26 cases, paired primary tumor specimens from the same patients prior to therapy were also available. Fifteen (28%) of the recurrent therapy-resistant tumors, but none of the untreated primary tumors, contained AR gene amplification as determined by fluorescence in situ hybridization. According to single-stranded conformation polymorphism analysis, the AR gene was wild type in all but one of the 13 AR amplified cases studied. In one tumor, a presumed mutation in the hormone-binding domain at codon 674 leading to a Gly --> Ala substitution was found, but functional studies indicated that this mutation did not change the transactivational properties of the receptor. AR amplification was associated with a substantially increased level of mRNA expression of the gene by in situ hybridization. Clinicopathological correlations indicated that AR amplification was most likely to occur in tumors that had initially responded well to endocrine therapy and whose response duration was more than 12 months. Tumors that recurred earlier or those that showed no initial therapy response did not contain AR amplification. The median survival time after recurrence was two times longer for patients with AR amplification in comparison to those with no amplification (P = 0.03, Willcoxon-Breslow test). In conclusion, failure of conventional androgen deprivation therapy in prostate cancer may be caused by a clonal expansion of tumor cells that are able to continue androgen-dependent growth despite of the low concentrations of serum androgens. Amplification and the increased expression of a wild-type AR gene may play a key role in this process.
Collapse
Affiliation(s)
- P Koivisto
- Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere, Finland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997; 31:216-9. [PMID: 9076469 DOI: 10.1159/000474453] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE We recently found amplification of the androgen receptor (AR) gene in approximately 30% of locally recurrent prostate carcinomas from patients treated by conventional androgen deprivation (castration) therapy, whereas none of the untreated primary prostate tumors showed this amplification. This suggests that AR gene amplification was selected during androgen deprivation therapy. The present case study represents our initial approach to evaluate the role that AR amplification may play in therapy resistance after other forms of endocrine therapy. MATERIAL AND METHODS Specimens from both a primary and a subsequent locally recurrent tumor were studied for amplification of the AR gene by fluorescence in situ hybridization from a prostate cancer patient who experienced tumor progression after monotherapy with the potent antiandrogen bicalutamide (Casodex, a trade mark, the property of Zeneca Ltd). RESULTS AND CONCLUSIONS High-level amplification of the AR gene was found in the recurrent tumor, whereas no evidence of amplification was found in the primary tumor. After recurrence, the patient first received chemotherapy (ifosfamide) for 15 weeks with no response, followed by maximal androgen blockade (MAB). The latter therapy resulted in a favorable short-term response. This case study has the following implications which warrant further research: (1) AR amplification may be selected not only by castration but also by therapy with a competitive peripheral androgen-receptor-blocking agent, and (2) recurrent tumors with AR amplification may be particularly likely to benefit from MAB as a second-line therapy.
Collapse
Affiliation(s)
- C Palmberg
- Division of Urology, Tampere University Hospital, Finland
| | | | | | | | | | | | | |
Collapse
|
17
|
Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995; 147:1608-14. [PMID: 7495286 PMCID: PMC1869969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The molecular mechanisms and genetic changes that lead to the progression of prostate cancer during endocrine therapy are poorly characterized. Here, paired specimens from both untreated primary tumors and from local recurrences were collected from 10 prostate cancer patients treated by conventional androgen deprivation therapy. The genetic progression of the tumors was studied by using interphase fluorescence in situ hybridization and chromosome-specific probes. Six primary tumors (60%) and all ten recurrent tumors were aneuploid by fluorescence in situ hybridization. The recurrent tumors also showed a high degree of chromosome copy number variability from one cell to another. Increased copy number of chromosome X was particularly common in the recurrent tumors. In addition, specific high level amplification of the androgen receptor (AR) gene (Xq12) was detected in three highly aneuploid recurrent tumors. Our findings suggest that hormone-refractory prostate cancers are genetically very complex and show intratumor genetic heterogeneity. Increased copy number of chromosome X and the amplification of the androgen receptor (AR) gene may confer proliferative advantage during androgen deprivation and thus contribute to the development of recurrence.
Collapse
Affiliation(s)
- P Koivisto
- Laboratory of Cancer Genetics, Tampere University, Institute of Medical Technology, Finland
| | | | | | | | | | | | | |
Collapse
|
18
|
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9:401-6. [PMID: 7795646 DOI: 10.1038/ng0495-401] [Citation(s) in RCA: 1004] [Impact Index Per Article: 34.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Overexpression of amplified genes is often associated with the acquisition of resistance to cancer therapeutic agents in vitro. We have identified a similar molecular mechanism in vivo for endocrine treatment failure in human prostate cancer which involves amplification of the androgen receptor (AR) gene. Comparative genomic hybridization shows that amplification of the Xq11-q13 region (the location), is common in tumours recurring during androgen deprivation therapy. We found high-level AR amplification in seven of 23 (30%) recurrent tumours, but in none of the specimens taken from the same patients prior to therapy. Our results suggest that AR amplification emerges during androgen deprivation therapy by facilitating tumour cell growth in low androgen concentrations.
Collapse
Affiliation(s)
- T Visakorpi
- Laboratory of Cancer Genetics, Tampere University Hospital, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|